Orgenesis Inc (NASDAQ:ORGS) has entered into a definitive agreement with MM OS Holdings, an affiliate of Metalmark Capital Partners, to acquire its approximate 25% stake in Octomera. Octomera is Orgenesis’s cell processing services subsidiary, and the transaction allows the company to have 100% ownership of this business unit. In exchange, Metalmark will receive a royalty of 5% of the net revenue of Octomera’s cell processing services for the three calendar years 2025-2027, along with a portion
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Orgenesis to acquire full ownership of Octomera & Metalmark to receive royalty & proceeds in exchange. Shift to decentralized production supported by regulators.
Name Change and Rebranding Reflects Progression of the Business and Focus on Changing the Paradigm of CGT Production GERMANTOWN, Md., July 11, 2023 (GLOBE…